Biocon Sustainability Profile
Biocon Limited, a leading biopharmaceutical company headquartered in Bengaluru, India, has established itself as a key player in the global biotechnology industry since its founding in 1978. With a strong focus on biopharmaceuticals, biosimilars, and novel biologics, Biocon operates across major regions including Asia, Europe, and North America. The company is renowned for its innovative products, particularly in the fields of diabetes, oncology, and autoimmune diseases. Biocon's commitment to affordability and accessibility sets it apart, making significant strides in providing high-quality healthcare solutions. Notable achievements include the launch of India's first biosimilar monoclonal antibody and recognition as a pioneer in the biosimilars market. With a robust pipeline and a reputation for excellence, Biocon continues to shape the future of biotechnology on a global scale.
DitchCarbon Score
How does Biocon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocon's score of 52 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biocon's reported carbon emissions
In 2025, Biocon reported total carbon emissions of approximately 23,898,000 kg CO2e from Scope 1 sources. The previous year, 2024, saw emissions of about 38,428,000 kg CO2e from Scope 1 and 116,989,000 kg CO2e from Scope 2, with an additional 126,110,000 kg CO2e from Scope 3 emissions. In 2023, Biocon's emissions included approximately 45,715,000 kg CO2e from Scope 1 and 138,510,000 kg CO2e from Scope 2. Biocon has set ambitious climate commitments, aiming for a 25% reduction in Scope 1 and Scope 2 emissions by the end of FY29, using FY20 as the baseline. Additionally, they have an internal target of a 20% reduction in these emissions by 2032, having already achieved a 14% reduction from the FY22 baseline. Furthermore, Syngene, a subsidiary, has committed to a 50% reduction in GHG emissions by FY33. Biocon's emissions data is not cascaded from any parent organization, and all reported figures are derived directly from their own disclosures. The company continues to focus on sustainability and reducing its carbon footprint in alignment with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 55,997,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 127,530,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 |
How Carbon Intensive is Biocon's Industry?
How Carbon Intensive is Biocon's Location?
Biocon's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biocon has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
